Trial Profile
A retrospective study to evaluate safety and efficacy of combination of lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2015
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 02 Nov 2015 New trial record